← Back to Search

ACE Inhibitor or Beta Blocker

1 for Heart Failure (MANTICORE Trial)

Phase 1 & 2
Waitlist Available
Led By Ian Paterson, MD FRCPC
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3.5 years
Awards & highlights

MANTICORE Trial Summary

While trastuzumab has been shown to prevent recurrences of breast cancer, some women may also experience damage to their heart muscle (including heart failure) as a result of their treatment. The investigators hope to learn if standard medications used in heart failure can prevent heart damage caused by trastuzumab in women with breast cancer. The investigators would also like to know if there are any ways to detect this damage earlier using magnetic resonance imaging (MRI) and blood tests.

Eligible Conditions
  • Heart Failure
  • Breast Cancer

MANTICORE Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3.5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3.5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
The primary objective is to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular (LV) remodeling among women with HER2+ early breast cancer.

MANTICORE Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
886 Previous Clinical Trials
384,809 Total Patients Enrolled
25 Trials studying Heart Failure
5,534 Patients Enrolled for Heart Failure
Ian Paterson, MD FRCPCPrincipal InvestigatorAlberta Health services

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Clinical Cancer ResearchJournal
Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training
Haykowsky, Mark J., John R. Mackey, Richard B. Thompson, Lee W. Jones, and D. Ian Paterson. 2009. “Adjuvant Trastuzumab Induces Ventricular Remodeling Despite Aerobic Exercise Training”. Clinical Cancer Research. American Association for Cancer Research (AACR). doi:10.1158/1078-0432.ccr-09-0628.
clinicaltrials.govStudy
Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research
2010. "Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01016886.
All > Oncology
~7 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top